KA/EN
Register
Medicines reference
Search
Search
Active substance

Ursodeoxycholic acid

Favourites

Bile acid, choleretic. Registered in Georgia: 1 human medicine. Forms: coated tablet.

Dose and use

Doses

Each dose comes with its source. Check the label of the product you use.

Active substance Ursodeoxycholic acid
Dose calculatorCalculates the active-substance amount; it is not a prescription.
PatientSpecies and weight will be filled in automatically in other calculators.
Selected dose
Dose Species Indication Route Frequency Source
15 mg/kg
off-label
 Dog, Cat Maintenance By mouth once daily
MSD Vet Manual 2024
Reference book
A veterinary reference written and reviewed by specialists, summarising accepted practice. The product label gives the authorised dose.
Drugs That Affect Digestive Functions in Monogastric Animals
MSD/Merck Veterinary Manual, 2024
Before use

Safety information

No sourced safety entry is currently shown. This does not mean the substance is risk-free.

Latin name
Ursodeoxycholic acid
Georgian name
ურსოდეზოქსიქოლის მჟავა
Authorisation status
Human medicine, cascade use
No veterinary authorisation was found in any register checked. Veterinary use is off-label, under the prescribing cascade.
Registered in Georgia
1 of 1 forms
Products
Ursovef
Human medicines in Georgia
Bilodeqol, Choleron, Choludexan, Grinterol, Surol, Ursactive, Ursobil HT, Ursofalk, Ursoflor, Ursomac, Ursomed, Ursosan, Ursosan Forte, Ursovef
Human medicines with this substance in the Georgian register of medicines (Ministry of Health), checked on 18 Oct 2026. They are human medicines, not veterinary products; strengths and forms differ.
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
All forms and registration1

Registration in Georgia and abroad: the register, number, validity and source are behind (i).

Ursovef 500 mg, Coated tablet

film-coated tablet, human medicine
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Adjunctive ursodeoxycholic-acid therapy for selected diagnosed canine cholestatic or inflammatory hepatobiliary disease after exclusion of complete extrahepatic obstruction
5.6/10
Weak evidence support
vetman assessment

Ursovef

500 mg, film-coated tablet, human medicine
Assessed clinical scopeDog · Adjunctive ursodeoxycholic-acid therapy for selected diagnosed canine cholestatic or inflammatory hepatobiliary disease after exclusion of complete extrahepatic obstruction · By mouth
Care settingVeterinarian-directed outpatient adjunct after hepatobiliary diagnosis and imaging, with accurate formulation selection, laboratory/ultrasound monitoring and urgent surgical escalation when obstruction, leakage or progression is suspected.
vetman score 5.6/10 Weak evidence support
Evidence confidence: Medium Georgia: Yes, human · № რ-037741 · Verified on 23 Oct 2026 Off-label use

A plausible guideline-supported adjunct for selected non-obstructed cholestatic disease, but exact-product veterinary evidence is limited and the 500 mg tablet is a poor dosing unit for many dogs.

Regulatory and scientific credibility5.5/10

Exact 500 mg identity, full human instruction, manufacturer and current Georgian human registration are traceable, but no veterinary authorisation or exact-product target-animal dossier exists; veterinary support comes from ingredient guidance and limited animal evidence.

Clinical efficacy5.5/10

Consensus and disease-specific guidance support a biologically coherent adjunct in cholestatic chronic hepatitis and selected non-obstructed biliary disease, but efficacy is little investigated, direct canine evidence includes a single case and it cannot replace surgery or cause-specific care.

Safety and tolerability6.5/10

UDCA is generally tolerated and the exact human label is detailed, but complete obstruction can make choleresis dangerous; diarrhoea, interaction-related underexposure, worsening biliary disease and unestablished canine reproductive/long-term exact-product safety require monitoring.

Clinical practicality4.5/10

Once-daily oral treatment can be simple in a large dog, but one 500 mg whole tablet fits about 33.3 kg at 15 mg/kg and the score is not validated for equal halves; most dogs require a lower strength or accurately prepared formulation plus repeated monitoring.

Full-course cost-effectiveness-

No verified current Georgian patient-adjusted full-course price is available, so cost is excluded.

Important safety and use flags

  • Human medicine registered in Georgia; dog/cat use is off-label and no veterinary authorisation or exact Ursovef target-animal dossier exists.
  • Adjunct only. Establish the hepatobiliary diagnosis and treat the cause; do not replace nutrition, antimicrobials, copper-directed or immune therapy, drainage, decompression or surgery when indicated.
  • Exclude complete extrahepatic bile-duct obstruction before use. Worsening pain, jaundice, fever, vomiting, effusion, gallbladder leakage/rupture or imaging progression requires urgent escalation, not more choleretic.
  • Use in gallbladder mucocele only when leakage/obstruction is absent and monitoring is close; progression makes surgery necessary, and cholecystectomy remains essential for most clinically significant obstruction/inflammation/rupture.
  • Veterinary reference dose is 15 mg/kg PO every 24 hours, while disease-specific schedules differ. Never transfer a human indication schedule or increase dose without diagnosis-specific evidence.
  • One intact 500 mg tablet approximates 33.3 kg at 15 mg/kg. The one-sided score is not documented to yield equal doses; do not claim half-tablet accuracy, crush or create visual fragments. Use a validated lower strength or accurately prepared formulation.
  • Monitor appetite, stool/diarrhoea, vomiting, pain, jaundice, liver enzymes, bilirubin and disease-appropriate ultrasound. Define response and stop/escalate if clinical, biochemical or imaging disease progresses.
  • Cholestyramine, colestipol and aluminium-containing antacids/smectite bind UDCA; separate by at least two hours. Review ciclosporin levels and possible ciprofloxacin underexposure when co-administered.
  • Avoid in known bile-acid/excipient hypersensitivity and reassess acute gallbladder/biliary inflammation, frequent biliary colic, calcified stones or impaired gallbladder contractility before exposing an animal.
  • Exact safety in pregnancy, lactation, breeding animals, puppies/kittens and prolonged or repeated dog/cat courses is not established; use only after individual benefit-risk review.
Assessment sources
  1. Ursovef manufacturer2026
  2. Vefa Ursovef KÜB2026
  3. Ursovef GE register2026
  4. MSD UDCA dose2026
  5. ACVIM canine hepatitis2019
  6. MSD canine mucocele2026
  7. MSD canine cholangitis2026
  8. Canine UDCA case1997
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat Adjunctive ursodeoxycholic-acid therapy for selected diagnosed feline hepatobiliary disease after exclusion of complete obstruction and destructive cholangitis
4.6/10
Weak evidence support
vetman assessment

Ursovef

500 mg, film-coated tablet, human medicine
Assessed clinical scopeCat · Adjunctive ursodeoxycholic-acid therapy for selected diagnosed feline hepatobiliary disease after exclusion of complete obstruction and destructive cholangitis · By mouth
Care settingVeterinarian-directed outpatient adjunct after hepatobiliary diagnosis and imaging, with accurate formulation selection, laboratory/ultrasound monitoring and urgent surgical escalation when obstruction, leakage or progression is suspected.
vetman score 4.6/10 Weak evidence support
Evidence confidence: Low Georgia: Yes, human · № რ-037741 · Verified on 23 Oct 2026 Off-label use

A narrowly useful but weakly evidenced feline adjunct only after excluding obstruction and destructive cholangitis; the 500 mg tablet is an especially unsuitable dose-delivery unit for most cats.

Regulatory and scientific credibility5.5/10

Exact 500 mg identity, full human instruction, manufacturer and current Georgian human registration are traceable, but no veterinary authorisation or exact-product target-animal dossier exists; veterinary support comes from ingredient guidance and limited animal evidence.

Clinical efficacy4.5/10

Mechanistic and general dog/cat guidance support selected adjunctive use, but direct feline outcome evidence is sparse and current guidance excludes destructive cholangitis because small-duct injury may worsen; broad hepatic-lipidosis or generic liver-support claims are not established.

Safety and tolerability5.5/10

General tolerability is reassuring, but complete obstruction and destructive cholangitis are material feline hazards; diarrhoea, worsening cholestasis, interaction-related underexposure and unestablished feline reproductive/long-term exact-product safety require monitoring.

Clinical practicality2.0/10

At 15 mg/kg a typical 4 kg cat needs about 60 mg, far below this 500 mg whole tablet; the score is not validated for equal halves and visual fragments are unsafe, making a lower strength or accurately prepared formulation essential.

Full-course cost-effectiveness-

No verified current Georgian patient-adjusted full-course price is available, so cost is excluded.

Important safety and use flags

  • Human medicine registered in Georgia; dog/cat use is off-label and no veterinary authorisation or exact Ursovef target-animal dossier exists.
  • Adjunct only. Establish the hepatobiliary diagnosis and treat the cause; do not replace nutrition, antimicrobials, copper-directed or immune therapy, drainage, decompression or surgery when indicated.
  • Exclude complete extrahepatic bile-duct obstruction before use. Worsening pain, jaundice, fever, vomiting, effusion, gallbladder leakage/rupture or imaging progression requires urgent escalation, not more choleretic.
  • Do not use for feline destructive cholangitis; current guidance warns that UDCA may provoke small-duct injury. Generic feline hepatic-lipidosis benefit is not established.
  • Veterinary reference dose is 15 mg/kg PO every 24 hours, while disease-specific schedules differ. Never transfer a human indication schedule or increase dose without diagnosis-specific evidence.
  • One intact 500 mg tablet approximates 33.3 kg at 15 mg/kg. The one-sided score is not documented to yield equal doses; do not claim half-tablet accuracy, crush or create visual fragments. Use a validated lower strength or accurately prepared formulation.
  • Monitor appetite, stool/diarrhoea, vomiting, pain, jaundice, liver enzymes, bilirubin and disease-appropriate ultrasound. Define response and stop/escalate if clinical, biochemical or imaging disease progresses.
  • Cholestyramine, colestipol and aluminium-containing antacids/smectite bind UDCA; separate by at least two hours. Review ciclosporin levels and possible ciprofloxacin underexposure when co-administered.
  • Avoid in known bile-acid/excipient hypersensitivity and reassess acute gallbladder/biliary inflammation, frequent biliary colic, calcified stones or impaired gallbladder contractility before exposing an animal.
  • Exact safety in pregnancy, lactation, breeding animals, puppies/kittens and prolonged or repeated dog/cat courses is not established; use only after individual benefit-risk review.
Assessment sources
  1. Ursovef manufacturer2026
  2. Vefa Ursovef KÜB2026
  3. Ursovef GE register2026
  4. MSD UDCA dose2026
  5. MSD feline cholangitis2026
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Ursodeoxycholic acid500 mg
Formulation Type
Coated tablet
Administration route
By mouth
Manufacturer
Vefa İlaç San. ve Tic. A.Ş. · Türkiye
Registration
Georgia Yes, human
In force until 15 Dec 2027
Human (Ministry of Health, RAMA)
In the register: Ursovef 500 mg film-coated tablet
№ რ-037741
Verified on: 23 Oct 2026
 EU Not confirmed
Verified on: 23 Oct 2026
 UK Not confirmed
Verified on: 23 Oct 2026
 US Not confirmed
Verified on: 23 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026

Professional reference for veterinary professionals. Not advertising and not a substitute for the product label/SPC.

For veterinary professionals only. It does not replace clinical judgement or the product label; check the dose in the official label (SPC). vetman is not liable for harm caused by using this information.

Trademarks belong to their owners; vetman is not affiliated with the manufacturers and receives no payment from them.

The database is protected under Chapter VII of the Law of Georgia on Copyright and Related Rights; automated or bulk copying is prohibited.

This reference is still growing. Missing a product? Let us know. · Report an error or request an addition · Updated: 23 Oct 2026

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.

Register Demo ↗